2020 Avon Court, #4
Charlottesville, VA 22902
434-220-0718
info@diffusionpharma.com
 RSS Feed
  • Home
  • About Us
    • Company History
    • Leadership Team
      • Management Team
        • David Kalergis, JD/MBA
        • John L. Gainer, PhD
        • Matthew W. Hantzmon
        • Ben Shealy, MBA/CFA
        • David R. Jones, M.D.
        • Kim Whitten, PharmD, RAC
        • Robert Murray, PhD
        • James Edward John, III
        • Kelly Hoy
        • Jenny Tornqvist, Ph.D.
        • Tracey Linkous Danner, CTM
      • Board of Directors
        • David Kalergis, JD/MBA
        • John L. Gainer, PhD
        • Mark T. Giles, JD
        • Thomas Byrne, JD
        • Robert W. Adams, JD
      • Scientific Advisory Board
        • John L. Gainer, PhD
        • Stuart A. Grossman, MD
        • John A. Jane, Sr., MD, Ph.D., FRCS(C), FACS
        • David R. Jones, M.D.
        • Guy M. Chisolm, Ph.D.
    • Patent Portfolio
    • News
      • Press Releases
      • Subscribe to our news
      • Key Contacts
    • Contact Us
    • Directions
  • Business Development
  • Investors
  • Pipeline
    • Patient Populations
    • Clinical Development of TSC
  • Science
    • Hypoxia and Hypoxic Conditions
    • Published Research
    • Our Scientific Collaborators

Archives

Year

  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004

Categories

  • Awards
  • Board
  • Funding
  • Media Coverage
  • Partners
  • Patents
  • Presentations
  • Progress
  • Research
  • Staff
  • Uncategorized

Archive for 2008

Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)

Tuesday, September 2nd, 2008

September is National Vascular Disease Awareness Month CHARLOTTESVILLE, VA – September 3, 2008 – Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing new drugs for the treatment of unmet medical needs, announced today that it has begun to enroll patients in a Phase I/II clinical trial of its lead drug candidate trans sodium crocetinate (TSC). [...]

Tags: cancer, Cardiovascular disease, clinical trial, intermittent claudication, National Vascular Disease Awareness Month, PAD, peripheral arterial disease, TSC
Posted in Progress, Research

Mark T. Giles Joins Diffusion Pharmaceuticals’ Board of Directors

Tuesday, June 10th, 2008

CHARLOTTESVILLE, VA – Tuesday, June 10, 2008 – Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing new drugs for the treatment of life-threatening unmet medical needs, today announced the addition of Mark T. Giles to its Board of Directors. Mr. Giles is the Chairman of the Board of Virginia National Bank in Charlottesville, Virginia. He [...]

Tags: board of directors, management, Mark T. Giles
Posted in Board, Progress

Diffusion Pharmaceuticals Announces Issuance of U.S. Patent No. 7351844, Titled “Bipolar Trans Carotenoid Salts and Their Uses”, for its

Tuesday, April 8th, 2008

CHARLOTTESVILLE, VA – Tuesday, April 8, 2008 – Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing drugs utilizing a novel method of action that enhances oxygen diffusion, today announced that it has been granted U.S. patent no. 7,351,844 entitled “Bipolar Trans Carotenoid Salts and Their Uses.” This patent includes claims to a family of first-in-class [...]

Posted in Patents, Progress



Home | About Us | Business Development | Investors | Pipeline | Science


BioNetwork East - Investment Challenge Winner

©2010 Diffusion Pharmaceuticals LLC
Terms of Use